Exploring the Booming Dry Eye Syndrome Treatment Industry Projected at US$9,521 Million by 2033 | FMI

The Global Dry Eye Syndrome Treatment Industry is on the brink of a significant transformation, with a projected Compound Annual Growth Rate (CAGR) of 6.4% over the forecast period. In 2023, the market is already valued at an impressive US$ 5,120 million and is expected to reach an estimated US$ 9,521 million by 2033.

Dry Eye Syndrome, a common ocular condition that affects millions worldwide, has prompted substantial advancements in treatment options. With this remarkable growth projection, the global Dry Eye Syndrome Treatment Industry is set to become a focal point of the healthcare industry in the coming years.

Claim Your Copy of the Report with Captivating Visuals Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1215

One such example is the Narayana Nethralaya, a super specialty eye hospital based out of India, a dedicated lab to diagnose and treat dry eyes. This lab aims to provide patients with awareness about eye lid problems such as Meibomian gland dysfunction, which lead to the development of dry eye syndrome.

Also, similar trend is observed in developed market such as U.S. Various government awareness campaigns and not for profit initiatives try to create awareness about the dry eye disease to the population that does not have access to eye care facilities. Eye Care America is an example of a public service organization run by the American Academy of Ophthalmology Foundation that provides free eye care through volunteer ophthalmologists.

Further, those who are age 65 or older and who have not seen an ophthalmologist in three or more years may be eligible to receive a comprehensive, medical eye exam and up to one year of care at no out-of-pocket cost. This consequently will increase the utilization of dry eye treatment products and drive the growth of the Dry Eye Syndrome Treatment Industry during the forecast period. .

Key Takeaways from Dry Eye Syndrome Treatment Industry Study

• Greater acceptance of artificial tears owing to improved patient comfort leads the artificial tears segment to account for the maximum share of 60.8% in 2021, expanding at 7.1% CAGR during the forecast period.
• By prescription, Rx prescriptions are projected to account for 71.3% of the market share in 2022 indicating highest demand, since majority of population visit hospitals to get the checkup done, in turn increasing the numbers of Rx prescriptions.
• Retail pharmacies, as distribution channel held the largest share of 60.8% in 2021 and is expected to grow with the same trend throughout the forecast period.
• By region, North America held the largest share of 37.6% of the Dry Eye Syndrome Treatment Industry in 2021 indicating the growth due to high prevalence and high treatment adoption rate in North America.

Revealing the hidden assumptions of the study. Ask the Expert.
https://www.futuremarketinsights.com/ask-question/rep-gb-1215

“Growing incidence of dry eye syndrome due to growing aging population, and long working hours (increase in screen time) to drive the demand of Dry Eye Syndrome treatment products over the Decade,” says the FMI Analyst

Who is winning?

Key Players :

• Allergen plc. (Abbvie)
• Novartis AG
• Otsuka Pharmaceuticals Co.Ltd.
• Bausch Health Companies Inc.
• Akron Inc.
• Johnson & Johnson Inc.
• Thea Pharmaceuticals Limited
• OASIS Medical
• Altaire Pharmaceuticals Inc.
• Boiron USA
• Similasan Corporation
• Scope Ophthalmics Ltd.
• Reckitt Benckiser Group PLC
• Medicom Healthcare Ltd
• FDC Limited.
• Lupin Limited
• Jamjoom Pharmaceuticals Co.
• Sentiss Pharma Private limited.

Some of the leading manufacturers of dry-eye-syndrome treatment market focuses on the product launch and approvals with global expansion objectives, thereby, enhancing their market presence.

• In January 2021, SIFI an Italy based international ophthalmic company launched SYNFO for moisturizing and lubrication in dry eye treatment.
• In December 2020, Alcon Canada announced the launch of its new product Systane an ultra-hydration lubricant eye drops preservative free containing Hyaluronic acid and HP-guar
• In November 2020, Santen Pharmaceutical launched Cationorm categorized as artificial tear for moisturisation and long lasting relief to dry eye.

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-1215

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Dry Eye Syndrome Treatment Industry is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights on Dry Eye Syndrome Treatment Industry segment based on Product (Cyclosporine, Topical Corticosteroids, and Artificial Tears Punctal Plugs (removable, dissolvable), oral omega supplements, and others), prescription (Rx, OTC, Medical Device), distribution channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, and Online Pharmacies) across seven major regions.

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube